At present, programmed cell death protein-1 (PD-1)/programmed cell death-ligand 1 (PD-L1) pathway inhibitors have achieved significant efficacy in immunotherapy for lung cancer, and PD-L1 has become the most commonly used predictive marker for immune checkpoint inhibitors (ICIs) of lung cancer. This evidence concerns the gene CD274 and lung cancer.